Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.

Antiviral therapy - 1 Jan 2008

Darwich Laila, Esteve Anna, Ruiz Lidia, Bellido Rocio, Clotet Bonaventura, Martinez-Picado Javier

Abstract excerpt

BACKGROUND: Selection and persistence of non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated mutations during treatment interruptions (TIs) has been attributed to the long plasma half-life of these drugs. However, little is known about the contribution of variable NNRTI plasma levels before a TI. We evaluated the selection of NNRTI-related mutations and the coefficient of variation of NNRTI plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to Cyclopropanes

Share to Drug Administration Schedule

Share to HIV Reverse Transcriptase

Share to Nevirapine

Share to Proviruses

Source

Identifiers

PMID: 19043929

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.PMID 19043929Read ↗

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.Semantic proximity Read ↗

Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients.Semantic proximity Read ↗

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.Semantic proximity Read ↗

Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.Semantic proximity Read ↗

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.Semantic proximity Read ↗

Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological FailureSemantic proximity Read ↗

Clinical implications of stopping nevirapine‐based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistanceSemantic proximity Read ↗

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.Semantic proximity Read ↗

Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.Semantic proximity Read ↗

Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.Semantic proximity Read ↗

Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.Semantic proximity Read ↗

Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.